title: CD103+Cell Growth Factor Flt3L Enhances the Efficacy of Immune Checkpoint Blockades in Murine Glioblastoma Model.
abstract: Glioblastoma is a lethal disease featuring a high proliferation of tumor cells, excessive angiogenesis, and heavy drug resistance. The overall survival of glioblastoma patients has been dismal, even with an intensive standard of care. Recent advances in immune checkpoint blockades are changing the treatment of cancers. However, the efficacy of immune checkpoint blockades in glioblastoma is still unclear. Here we investigated the roles of CD103+ cells in regulating the effect of immune checkpoint blockades in glioblastoma mouse models. Our findings indicated that the murine glioblastoma model was not sensitive to immune checkpoint blockades. Flt3L, a growth factor for CD103+ cells, could significantly increase the number of CD103+ dendritic cells in the murine glioblastoma model and, thus, sensitize murine glioblastoma to immune checkpoint blockades. Downstream analysis indicated that the Flt3L and immune checkpoint blockade combination increased the number of tumor-infiltrating CD8+ cells, decreased immune checkpoint expression, and therefore enhanced the antitumor immune response in the murine glioblastoma model. These findings suggested that Flt3L could enhance the efficacy of immune checkpoint blockades in glioblastoma via expanding CD103+ dendritic cells and downstream antitumor immune response.
authors.affiliation: Eye Hospital of Wenzhou Medical University, Zhejiang, P.R. China.
authors.forename: Xiaolin
authors.initials: X
authors.lastname: Miao
authors.affiliation: Eye Hospital of Wenzhou Medical University, Zhejiang, P.R. China.
authors.forename: Yiqi
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Research Center of Blood Transfusion Medicine, Education Ministry Key Laboratory of Laboratory Medicine, Zhejiang Provincial People's Hospital, Zhejiang, P.R. China.
authors.forename: Ke
authors.initials: K
authors.lastname: Hao
authors.affiliation: School of Laboratory Medicine and Life Science, Wenzhou Medical University, Zhejiang, P.R. China.
authors.forename: Meiqin
authors.initials: M
authors.lastname: Zheng
authors.affiliation: Research Center of Blood Transfusion Medicine, Education Ministry Key Laboratory of Laboratory Medicine, Zhejiang Provincial People's Hospital, Zhejiang, P.R. China.
authors.forename: Bingyu
authors.initials: B
authors.lastname: Chen
authors.affiliation: Research Center of Blood Transfusion Medicine, Education Ministry Key Laboratory of Laboratory Medicine, Zhejiang Provincial People's Hospital, Zhejiang, P.R. China.
authors.forename: Kaiqiang
authors.initials: K
authors.lastname: Li
authors.affiliation: Research Center of Blood Transfusion Medicine, Education Ministry Key Laboratory of Laboratory Medicine, Zhejiang Provincial People's Hospital, Zhejiang, P.R. China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Clinical Research Institute, Zhejiang Provincial People's Hospital, Zhejiang, P.R. China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Clinical Research Institute, Zhejiang Provincial People's Hospital, Zhejiang, P.R. China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Clinical Research Institute, Zhejiang Provincial People's Hospital, Zhejiang, P.R. China.
authors.forename: Xiaozhou
authors.initials: X
authors.lastname: Mou
authors.affiliation: Department of Gynecology, Zhejiang Provincial People's Hospital, Zhejiang, P.R. China.
authors.forename: Shanshan
authors.initials: S
authors.lastname: Jiang
authors.affiliation: School of Laboratory Medicine and Life Science, Wenzhou Medical University, Zhejiang, P.R. China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Wang
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000378:metabolism*; D000074322:Antineoplastic Agents, Immunological / Q000494:pharmacology; D015415:Biomarkers; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism*; D004195:Disease Models, Animal; D005909:Glioblastoma / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects; D039001:Integrin alpha Chains / Q000378:metabolism*; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008565:Membrane Proteins / Q000378:metabolism*; D051379:Mice; D058990:Molecular Targeted Therapy; D023041:Xenograft Model Antitumor Assays
chemical_list: D015703:Antigens, CD; D000074322:Antineoplastic Agents, Immunological; D015415:Biomarkers; D014408:Biomarkers, Tumor; D039001:Integrin alpha Chains; D008565:Membrane Proteins; C091367:alpha E integrins; C084881:flt3 ligand protein